# NGS as the First-line Treatment in Advanced Biliary Tract Cancer

> **NCT04172402** · PHASE2 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 48 (actual)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** TS-1
- **DRUG:** Gemcitabine
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04172402
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-27
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172402, "NGS as the First-line Treatment in Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04172402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*